Sjögren's disease (SjD)

What changes during this transition

Sjögren's Disease is a systemic autoimmune exocrinopathy — not a dry-eye condition with extraglandular features, but a B-cell-driven autoimmune disease whose dryness symptoms are the most visible manifestation of lymphocytic infiltration of salivary and lacrimal glands. The ACR/EULAR 2016 classification criteria require objective evidence (focus score ≥1 on minor salivary gland biopsy, anti-Ro/SSA positivity, abnormal Schirmer / ocular staining / unstimulated salivary flow). Female predominance runs ~9:1. Roughly 5% of patients develop MALT lymphoma over their lifetime — surveillance for parotid swelling, monoclonal gammopathy, and persistent gland enlargement is load-bearing, not optional. The therapeutic landscape is moving for the first time in 30 years. Ianalumab (anti-BAFF monoclonal, Novartis) hit positive Phase 3 readouts in the NEPTUNUS program in 2024 — the first plausible disease-modifying therapy for SjD with regulatory submission expected. Iscalimab (anti-CD40, Novartis) failed Phase 3 in 2024 in the same year — the CD40-CD40L axis remains a target but iscalimab itself is out. Dazodalibep (anti-CD40L, now Amgen) is still in Phase 3. CD19 CAR-T is in compassionate use for refractory severe extraglandular disease. The B-cell depletion paradigm — long debated after the TEARS and TRACTISS rituximab trials read out mixed — is now being re-tested with smarter targets. Standard-of-care backdrop is rheumatology-led: artificial tears, cyclosporine ophthalmic emulsion (Restasis/Cequa), lifitegrast (Xiidra), perfluorohexyloctane (Miebo, FDA-approved August 2023) for evaporative dry eye, pilocarpine and cevimeline for sicca symptoms, hydroxychloroquine widely used for fatigue/arthralgia despite no large RCT support (EULAR 2019), methotrexate or leflunomide for articular involvement, and rituximab off-label for severe extraglandular manifestations (cryoglobulinemia, vasculitis, mononeuritis multiplex). EULAR 2019 and ACR 2020 guidelines anchor the protocol. The Sjögren's Foundation patient organization is the lay-facing reference. Anti-Ro/SSA-positive patients of childbearing potential require pre-pregnancy counseling: maternal anti-Ro crosses the placenta and causes neonatal lupus (~2% risk of congenital heart block, higher in subsequent pregnancies after an affected child). Where Juno's library fits — narrowly and with deliberate non-elevation. No peptide has Phase 2/3 Sjögren's-specific evidence. The five drafted substrate entries (TB-500, Selank, Thymosin alpha-1, BPC-157, KPV) exist for honest /ask answers when users probe specific compounds. TB-500 has the closest editorial adjacency through RegeneRx's RGN-259 ophthalmic program (Phase 3 work in neurotrophic keratopathy and dry-eye signal in earlier trials) — Sjögren's dry eye overlaps with the population studied, but the compounded peptide-channel TB-500 is editorially separate from the program-grade ophthalmic formulation, and surfacing TB-500 as a discovery card would mislead. Selank addresses comorbid anxiety/fatigue (30-50% prevalence in published SjD cohorts) but not the autoimmune disease. Thymosin alpha-1 raises a directional concern — Th1 bias in a Th1-driven autoimmune disease. BPC-157 conflates wound-healing mechanism with autoimmune gland destruction. KPV's anti-inflammatory framing is a long chain to B-cell-driven autoimmunity. The honest editorial frame: rheumatology-led multi-specialty coordination (rheum + ophth + dental, sometimes GI/neuro), ACR/EULAR 2016 classification + serology + biopsy + objective ocular/salivary measures, symptom-layer standard of care (cyclosporine/lifitegrast/Miebo for ocular, pilocarpine/cevimeline for sicca, hydroxychloroquine for fatigue/arthralgia), MALT lymphoma surveillance, anti-Ro/SSA mother neonatal lupus counseling, and the rapidly-evolving disease-modifying pipeline (ianalumab NEPTUNUS positive 2024) drive outcomes.